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Mildly impaired renal function is associated with cardiovascular morbidity and mortality. There are indications that
endothelial dysfunction and/or chronic inflammation, which play an important role in atherothrombosis, are present in early
stages of renal insufficiency. This study investigated whether and to which extent endothelial dysfunction and inflammation
were related to renal function and contributed to renal function–associated cardiovascular mortality in a population-based
cohort (n  613), aged 50 to 75 yr, that was followed with a median duration of 12.5 yr. During follow-up, 192 individuals died
(67 of cardiovascular causes). At baseline, renal function was estimated with serum creatinine, the Cockcroft-Gault formula,
and the Modification of Diet in Renal Disease equation of GFR (eGFR). Endothelial function was estimated by plasma von
Willebrand factor, soluble vascular cell adhesion molecule-1, and the urinary albumin-creatinine ratio. Inflammatory activity
was estimated by plasma C-reactive protein and soluble intercellular adhesion molecule-1. Renal function was mildly
impaired (mean eGFR 68  12 ml/min per 1.73 m2) and independently associated with von Willebrand factor (standardized
 0.09; 95% confidence interval [CI] 0.18 to 0.002; P < 0.05), soluble vascular cell adhesion molecule-1 (standardized 
0.14; 95% CI 0.22 to 0.05; P < 0.01), and albumin-creatinine ratio (standardized  0.15; 95% CI 0.23 to 0.08; P < 0.001)
but not with markers of inflammatory activity. Renal function was inversely associated with cardiovascular and all-cause
mortality. The relative risk for cardiovascular mortality but not all-cause mortality associated with renal function decreased
from 1.22 to 1.12 per 5 ml/min per 1.73 m2 decrease of eGFR after adjustment for markers of endothelial dysfunction. In
conclusion, endothelial dysfunction was related to renal function and contributed to the excess in cardiovascular mortality in
this population-based cohort with mild renal insufficiency.
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C hronic kidney disease (CKD) is a prevalent healthproblem, involving10% of the general population ofthe United States (1). CKD, especially ESRD, is
strongly associated with the occurrence of cardiovascular dis-
ease (2). As recently demonstrated, even mildly impaired renal
function is associated with cardiovascular morbidity (3,4) and
mortality (3,5). Although CKD is associated with several risk
factors for cardiovascular disease, such as male gender, older
age, hyperhomocysteinemia, hypertension, smoking, diabetes,
obesity, and pre-existing cardiovascular disease, the excess car-
diovascular risk in CKD is not fully explained by this clustering
of conventional risk factors.
In atherogenesis, endothelial dysfunction and inflammation
are important and interrelated early steps (6). Indeed, several
biochemical markers of endothelial dysfunction and inflamma-
tory activity have been shown to be independent risk factors of
cardiovascular morbidity and mortality (7–11). It is unknown
whether the excess cardiovascular risk in CKD is (partially)
attributable to endothelial dysfunction and inflammation.
There is evidence that a decreased GFR is associated with
endothelial dysfunction as well as inflammatory activity (12–
14). However, there is little evidence that a low GFR is associ-
ated with endothelial dysfunction and inflammation in the
general population and, if so, whether any such associations
can explain the association of a low GFR with risk for cardio-
vascular disease.
In view of these considerations, we investigated, in a pro-
spective, population-based study (1) whether estimates of GFR
were cross-sectionally associated with markers of endothelial
dysfunction and inflammatory activity at the baseline exami-
nation and (2) whether endothelial dysfunction and inflamma-
tory activity were involved in the excess mortality associated
with a low GFR.
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Materials and Methods
Participants
The study population consisted of an age-, gender-, and glucose
tolerance–stratified sample of the Hoorn Study, a population-based
study of glucose tolerance and other cardiovascular risk factors in a 50-
to 75-yr-old general white population conducted from 1989 to 1992, as
described previously (15).
Briefly, 2484 people (71% of those invited) participated. All partici-
pants, except for those who had previously diagnosed diabetes and
were treated with oral glucose-lowering agents or insulin, underwent
an oral glucose tolerance test (OGTT) according to the World Health
Organization guidelines (16). For reasons of efficiency, participants
with a 2-h postload glucose 7.5 mmol/L, all participants with type 2
diabetes, and a random sample of participants with a 2-h postload
glucose 7.5 mmol/L stratified by age and gender were invited within
4 wk for a second visit to investigate glucose intolerance–related com-
plications (709 invited, 631 [89%] of whom participated).
These participants underwent a second OGTT (except those who
already used blood glucose–lowering agents; n  67). On the basis of
the mean of the two OGTT, glucose tolerance status was divided into
three categories according to the 1999 World Health Organization
criteria: Normal glucose metabolism, impaired glucose metabolism,
and type 2 diabetes (17). Participants in our study population thus
represented a stratified random sample of all participants in the initial
cohort.
The Hoorn Study was approved by the Ethical Review Committee of
the VU University Medical Center. Informed consent was obtained
from all participants.
Baseline Laboratory and Clinical Assessments
C-reactive protein (CRP) and soluble intercellular adhesion mole-
cule-1 (sICAM-1) were measured as markers of inflammatory activity,
and soluble vascular cell adhesion molecule-1 (sVCAM-1), von Wille-
brand factor (vWf), and microalbuminuria were measured as markers
of endothelial dysfunction. After an overnight fast, blood was drawn
from an antecubital vein. We measured blood concentrations of vWf,
sVCAM-1, CRP, sICAM-1, total (free plus bound) homocysteine, glu-
cose, creatinine, albumin, urea nitrogen, and lipids, as described else-
where (10,15). The urinary albumin-creatinine ratio (ACR) was calcu-
lated.
Creatinine clearance was estimated (eCC) by the Cockcroft-Gault
formula [(140  age)  (1.23  body weight/creatinine), amplified by
0.85 if female] (18). GFR was estimated (eGFR) by the Modification of
Diet in Renal Disease (MDRD) equation [170  (creatinine)0.999
(age)0.176 (serum urea nitrogen)0.170 (albumin)0.318 (0.762 if pa-
tient is female) (1.180 if patient is black)] (MDRD equation is given in
traditional units. To convert to International System units, multiply
creatinine in mg/dl by 88.4, urea in mg/dl by 0.357, and albumin in
g/dl by 10.) (19). eCC and eGFR were expressed in ml/min per 1.73 m2
body surface area. BP was measured as the mean of four measurements
performed on two different occasions, using a random-zero sphygmo-
manometer under standardized conditions. Participants were classified
as current cigarette smokers or nonsmokers. Body mass index (BMI)
and waist-to-hip ratio were calculated as described elsewhere (15).
Cardiovascular disease was defined as coronary artery disease, cere-
brovascular disease, and/or peripheral arterial disease.
We excluded individuals for whom no data were available for cal-
culation of the renal function estimates (n 18), leaving 613 individuals
available for analysis. From these individuals, data on vWf and
sVCAM-1 were missing in 21, data on ACR in 23, and data on CRP and
sICAM-1 in 23.
Follow-Up
Data on the participants’ vital status on January 1, 2004, were col-
lected from the mortality register of the municipality of Hoorn. Of 51
participants who had moved out of town, information was obtained
from the local municipalities. Of the 613 included participants, one was
lost to follow-up. For the other 612 participants, we determined
whether death had occurred during follow-up and, if so, the date when
death occurred. For all participants who had died, the cause of death
was extracted from the medical records of the general practitioner and
the hospital of Hoorn and classified according to the International
Classification of Diseases, Ninth Revision (20). Cardiovascular mortality
was defined as codes 390 to 459.
Statistical Analyses
All analyses were performed with the SPSS, version 11.5 (SPSS Inc.,
Chicago, IL). Variables are presented as mean  SD, number (percent-
age of the total), or, in case of a skewed distribution, the median and the
interquartile range.
For descriptive purposes, the group was divided in tertiles according
to the eGFR. P value for trend over tertiles was calculated with univar-
iate ANOVA for continuous variables and with 2 test for binary
variables. Pearson test was used to assess correlation coefficients.
To study whether biochemical markers of endothelial dysfunction
and inflammatory activity were related independently to estimates of
renal function, regression analyses were performed with three different
models. In the first model—because of the stratification procedure—
multivariate regression analysis was performed with adjustment for
age, gender, and glucose tolerance status. In the second model, we
additionally adjusted for potential confounders, i.e., previous cardio-
vascular disease, systolic BP, current smoking, waist-to-hip ratio, total
cholesterol, and homocysteine. Finally, we adjusted the associations
between renal function and endothelial dysfunction markers for mark-
ers of inflammation, and vice versa. Variables that did not have a normal
distribution of the residuals (vWf, ACR, and CRP) were transformed
into their natural logarithm (ln) for a better fit of the data. Results are
described as standardized  with 95% confidence intervals (CI). Mul-
tivariate Cox regression analyses were performed to assess whether the
associations of renal function with all-cause mortality and cardiovas-
cular mortality were independent of potential confounding or mediat-
ing factors.
Adjustment for endothelial function was performed by adding each
marker of endothelial dysfunction separately to the model and by
adding vWf, sVCAM-1, and ACR simultaneously. Because microalbu-
minuria has been shown previously to have a heterogeneous associa-
tion with endothelial dysfunction in the Hoorn Study (21,22), we also
adjusted for sVCAM-1 and vWf only. In an additional analysis, sI-
CAM-1 was added to vWf, sVCAM-1, and ACR, because it has been
suggested that sICAM-1 may reflect endothelial dysfunction as well as
inflammatory activity. Adjustment for inflammatory activity was per-
formed by adding CRP and sICAM-1 (separately and simultaneously)
to the model.
Results are described as relative risks (RR; hazard ratios) with 95% CI
associated with a decrease in eGFR and eCC of 5 ml/min per 1.73 m2
and increase in serum creatinine concentration of 5 mol/L. Two-sided
P  0.05 was considered to reflect statistical significance.
Results
Table 1 shows the baseline characteristics of the study pop-
ulation according to tertiles of eGFR. In the whole study pop-
ulation, eGFR was 68  12 ml/min per 1.73 m2, eCC was 74 
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17 ml/min per 1.73 m2, and serum creatinine was 92  19
mol/L.
Relationship between Renal Function and Endothelial
Function
Table 2 shows that eGFR was independently associated with
vWf, sVCAM-1, and ACR in all models (see also Figure 1, A
through C).
Relationship between Renal Function and
Inflammatory Activity
None of the inflammatory markers was related indepen-
dently to any of the estimates of renal function (Table 3 and
Figure 1, D and E). In model 1, a significant positive association
was found between CRP and eCC, which, however, was not
present after adjustment for BMI (standardized  0.03; 95% CI
0.07 to 0.14; P  0.58), one of the dependent variables in
models 2 and 3. BMI was higher in participants with a higher
eGFR (Table 1) and strongly positively related with CRP
(model 3: 0.20; 95% CI 0.11 to 0.28; P  0.001).
Renal Function, Endothelial Dysfunction and Inflammatory
Activity in Relation to Cardiovascular and All-Cause Mortality
Median duration of follow-up was 12.5 yr (interquartile
range 9.9 to 13.2). During follow-up, 192 of 613 individuals died
(67 of cardiovascular disease and 31 of unknown causes). Renal
function, whether expressed as eGFR, eCC, or serum creatinine,
was inversely associated with risk for cardiovascular and all-
cause mortality. After adjustment for age, gender, glucose tol-
erance, systolic BP, and previous cardiovascular disease, the RR
(95% CI) of cardiovascular and all-cause mortality associated
with a decrease of 5 ml/min per 1.73 m2 of eGFR were 1.22 (1.09
to 1.36) and 1.12 (1.05 to 1.20), respectively (Tables 4 and 5). The
Table 1. Baseline characteristics of all participantsa
Tertiles of eGFR
P Value
(Trend)
First
(n  204)
72 ml/min
per 1.73 m²
Second
(n  205)
63 to 72 ml/min
per 1.73 m²
Third
(n  204)
63 ml/min
per 1.73 m²
eGFR (ml/min per 1.73 m2) 80 7 68 3 55 8 0.001
eCC (ml/min per 1.73 m2) 86 16 74 12 62 14 0.001
Serum creatinine (mol/L) 82 11 90 12 104 24 0.001
Male gender (n %	) 133 (65) 109 (53) 135 (66) 0.84
Age (yr) 62 7 63 7 67 6 0.001
Normal glucose metabolism (n %	) 77 (38) 94 (46) 79 (39) 0.84
Impaired glucose metabolism (n %	) 56 (28) 60 (29) 57 (28) 0.91
Type 2 diabetes (n %	) 71 (35) 51 (25) 68 (33) 0.75
BMI (kg/m2) 26.7 3.6 26.8 3.5 28.1 4.4 0.001
Waist-to-hip ratio (cm/cm) 0.94 0.09 0.90 0.08 0.92 0.08 0.01
Total cholesterol (mmol/L) 6.5 1.2 6.7 1.2 6.7 1.2 0.06
HDL cholesterol (mmol/l) 1.3 0.4 1.3 0.3 1.3 0.3 0.98
Lipid-lowering medication (n %	) 5 (2) 1 (0) 3 (1) 0.41
Systolic BP (mmHg) 138 20 136 19 144 19 0.01
Diastolic BP (mmHg) 83 10 82 10 83 10 0.82
Pulse pressure (mmHg) 55 15 54 13 62 16 0.001
BP-lowering medication (n %	) 52 (25) 40 (20) 77 (40) 0.01
Hypertension (n %	) 108 (53) 90 (44) 136 (67) 0.01
Current smokers (n %	) 63 (31) 52 (25) 41 (20) 0.05
Previous cardiovascular disease (n %	) 47 (23) 43 (21) 52 (26) 0.56
Homocysteine (mol/L) 11.2 4.2 12.5 5.9 13.9 6.3 0.001
vWf (IU/ml) 110 (88–162) 108 (74–166) 134 (89–188) 0.05
sVCAM-1 (g/L) 1304 423 1325 368 1512 515 0.001
Urinary ACR (mg/mmol) 0.77 (0.54 to 1.21) 0.87 (0.59 to 1.28) 0.99 (0.65 to 1.72) 0.05
C-reactive protein (mg/l) 1.75 (0.88 to 3.44) 1.49 (0.59 to 3.02) 2.13 (1.02 to 4.27) 0.74
sICAM-1 (g/L) 495 190 462 149 488 146 0.67
aValues for continuous variables are presented as mean  SD or median (interquartile range). P value for trend was
calculated with univariate ANOVA for continuous variables and with 2 test for dichotomous variables. Hypertension was
defined as a BP 140 mmHg systolic and/or 90 mmHg diastolic and/or the current use of BP-lowering medication. eGFR,
estimated GFR; eCC, estimated creatinine clearance; BMI, body mass index; vWf, Von Willebrand factor; sVCAM-1, soluble
vascular cell adhesion molecule-1; ACR, albumin-creatinine ratio; sICAM-1, soluble intercellular adhesion molecule-1.
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relationship between eGFR and cardiovascular mortality is
shown in Figure 2. The association was stronger for eGFR than
for eCC or serum creatinine (Table 4).
When vWf, sVCAM-1, andACRwere added individually to the
model, the RR for cardiovascular mortality associated with renal
function decreased from 1.22 to 1.21, 1.16, and 1.17, respectively
(Table 4, models 3 through 5). When the three markers were
added simultaneously, the RR decreased from 1.22 to 1.12 (Table
4, model 6). Adjustment for vWf and sVCAM-1 without ACR
decreased the RR from 1.22 to 1.16 (Table 4, model 7). After
addition of sICAM-1 to the three endothelial markers, the RR
decreased from 1.22 to 1.13 (Table 4, model 8). The RR for all-cause
Figure 1. Relations between estimated GFR and markers of endothelial dysfunction (von Willebrand factor [A], soluble vascular
cell adhesion molecule-1 [B], and urinary albumin-creatinine ratio [C]) and inflammatory activity (C-reactive protein [D], soluble
intercellular adhesion molecule-1 [E]). r, correlation coefficient.
Table 2. Relation of renal function with markers of endothelial functiona
Model
vWf sVCAM-1 Urinary ACR
Stand.  95% CI Stand.  95% CI Stand.  95% CI
1: Age, gender, glucose tolerance status
eGFR 0.11b 0.20 to0.02 0.23d 0.32 to 0.15 0.20d 0.28 to 0.12
eCC 0.02 0.15 to 0.10 0.15c 0.24 to 0.05 0.13c 0.23 to 0.02
serum creatinine 0.07 0.00 to 0.14 0.25d 0.17 to 0.34 0.27d 0.190.35
2: Model 1  previous cardiovascular disease, systolic BP, current smoking, BMI, total cholesterol, homocysteine
eGFR 0.10b 0.19 to0.001 0.18d 0.27 to 0.10 0.14c 0.22 to 0.06
eCC 0.05 0.18 to 0.07 0.16c 0.28 to 0.05 0.17c 0.28 to 0.06
serum creatinine 0.05 0.00 to 0.15 0.18d 0.09 to 0.27 0.17d 0.09 to 0.25
3: Model 2  C-reactive protein, sICAM-1
eGFR 0.09b 0.18 to 0.00 0.14c 0.22 to 0.05 0.15d 0.23 to 0.08
eCC 0.05 0.17 to 0.08 0.11b 0.22 to 0.01 0.18c 0.29 to 0.07
serum creatinine 0.04 0.03 to 0.11 0.11b 0.02 to 0.19 0.18d 0.10 to 0.25
avWf, urinary ACR, and C-reactive protein were transformed to natural logarithm (ln). Stand., standardized; CI, confidence interval.
bP  0.05; cP  0.01; dP  0.001.
540 Journal of the American Society of Nephrology J Am Soc Nephrol 17: 537–545, 2006
mortality associated with renal function was not materially af-
fected by these markers of endothelial dysfunction (Table 5). Ad-
justment for markers of inflammatory activity did not change
substantially the RR for cardiovascular (Table 4) or all-cause (Ta-
ble 5) mortality associated with renal function. Sequential inclu-
sion of smoking status, BMI (or hip-to-waist ratio), total choles-
terol (or HDL cholesterol), use of lipid-lowering medication, and
homocysteine as independent variables in model 2 of the Cox
regression analysis did not materially change the effect of adjust-
ment for the different markers of endothelial function and/or
inflammation on the renal function–associated cardiovascular and
all-cause mortality (data not shown).
Additional Analyses
Because age and gender are part of the Cockcroft-Gault for-
mula and the MDRD equation and were added to the analyses
with serum creatinine as key independent variable, all models
were tested without these (stratification) variables. This did not
materially influence our results (data not shown).
In the multivariate and Cox regression analyses, replacement
of systolic BP by diastolic BP, pulse pressure, presence of hy-
pertension, or use of BP-lowering medication did not materially
change the relation between renal function and markers of
endothelial dysfunction or inflammatory activity (data not
shown). In addition, we repeated all analyses after exclusion of
Table 4. Relative risks of cardiovascular mortality associated with estimates of renal functiona
Model
eGFR (RR 95%
CI	 Associated
with a Decrease of
5 ml/min per 1.73 m2)
eCC (RR 95%
CI	 Associated
with a Decrease of
5 ml/min per 1.73 m2)
Serum Creatinine
(RR 95%
CI	 Associated
with an Increase
of 5 mol/L)
1: Age, gender, glucose tolerance status 1.22b (1.09 to 1.36) 1.10c (1.01 to 1.21) 1.11b (1.07 to 1.16)
2: Model 1  previous cardiovascular
disease, systolic BP
1.22b (1.09 to 1.36) 1.12c (1.02 to 1.23) 1.11b (1.06 to 1.16)
3: Model 2  vWf 1.21d (1.08 to 1.35) 1.12c (1.02 to 1.23) 1.10b (1.06 to 1.15)
4: Model 2  sVCAM-1 1.16d (1.04 to 1.30) 1.08 (0.99 to 1.19) 1.09b (1.04 to 1.14)
5: Model 2  urinary ACR 1.17d (1.04 to 1.31) 1.09 (0.99 to 1.19) 1.09b (1.04 to 1.14)
6: Model 2  vWf, sVCAM-1, ACR 1.12c (1.00 to 1.26) 1.07 (0.98 to 1.17) 1.08d (1.02 to 1.13)
7: Model 6  urinary ACR 1.16c (1.04 to 1.30) 1.09 (0.99 to 1.19) 1.09b (1.04 to 1.14)
8: Model 6  sICAM-1 1.13c (1.01 to 1.27) 1.06 (0.97 to 1.17) 1.07d (1.02 to 1.13)
9: Model 2  C-reactive protein 1.22d (1.09 to 1.36) 1.12c (1.02 to 1.23) 1.11b (1.06 to 1.16)
10: Model 2  sICAM-1 1.20d (1.08 to 1.34) 1.10 (1.00 to 1.21) 1.10b (1.05 to 1.15)
11: Model 2  C-reactive protein, sICAM-1 1.20d (1.07 to 1.34) 1.10c (1.00 to 1.22) 1.10b (1.05 to 1.15)
avWF, urinary ACR, and C-reactive protein were transformed to natural logarithm (ln). RR, relative risk.
bP  0.001; cP  0.05; dP  0.01.
Table 3. Relation of renal function with markers of inflammatory activitya
Model
C-Reactive Protein sICAM-1
Stand.  95% CI Stand.  95% CI
1: Age, gender, glucose tolerance status
eGFR 0.00 0.07 to 0.08 0.02 0.10 to 0.07
eCC 0.14b 0.04 to 0.25 0.03 0.12 to 0.07
serum creatinine 0.03 0.07 to 0.12 0.07 0.01 to 0.16
2: Model 1  previous cardiovascular disease, systolic BP, current smoking, BMI, total cholesterol, homocysteine
eGFR 0.04 0.05 to 0.13 0.02 0.08 to 0.11
eCC 0.04 0.06 to 0.15 0.03 0.15 to 0.09
serum creatinine 0.01 0.09 to 0.08 0.01 0.08 to 0.11
3: Model 2  vWf, sVCAM-1, urinary ACR
eGFR 0.07 0.03 to 0.16 0.06 0.03 to 0.15
eCC 0.07 0.06 to 0.20 0.02 0.14 to 0.10
serum creatinine 0.04 0.12 to 0.05 0.03 0.12 to 0.06
aC-reactive protein, vWf, and urinary ACR were transformed to natural logarithm (ln).
bP  0.01.
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the four patients with CKD stage 4 (eGFR 15 to 29 ml/min per
1.73 m2) (1), which again did not materially change the results.
Further analyses to exclude the presence of effect modifica-
tion by the presence of diabetes, older age (65 yr), male
gender, or hypertension confirmed the consistency of the re-
sults, as the associations between renal function and biochem-
ical markers of inflammatory activity and endothelial dysfunc-
tion and between eGFR and mortality were similar regardless
of the presence or absence of these states (data not shown).
Discussion
This population-based study had three main findings. First,
mild impairment of renal function was independently associ-
ated with endothelial dysfunction. Second, we confirm and
extend our previous finding (5) of an association between mild
impairment of renal function and cardiovascular mortality (and
to a lesser extent all-cause mortality) that was independent of
conventional risk factors and that persisted during up to 13 yr
of follow-up. Third, endothelial dysfunction seemed to be in-
volved in this renal function–associated cardiovascular mortality.
An increasing number of studies show that individuals with
even mildly impaired renal function are at high risk for cardio-
vascular morbidity and mortality, independent of traditional
risk factors (2). We have proposed that endothelial dysfunction
and/or inflammation may be (partially) responsible for this
phenomenon (14). This was based on the general view that
Table 5. Relative risks for all-cause mortality associated with estimates of renal function
Model
eGFR (RR 95% CI	
Associated with a
Decrease of 5 ml/min
per 1.73 m2)
eCC (RR 95% CI	
Associated with a
Decrease of 5 ml/min
per 1.73 m2)
Serum Creatinine
(RR 95% CI	
Associated with an
Increase of 5 mol/L)
1: Age, gender, glucose tolerance status 1.12b (1.04 to 1.19) 1.03 (0.98 to 1.09) 1.08c (1.04 to 1.11)
2: Model 1  previous cardiovascular disease,
systolic BP
1.12b (1.05 to 1.20) 1.04 (0.98 to 1.09) 1.08c (1.04 to 1.11)
3: Model 2  vWf 1.11b (1.04 to 1.19) 1.04 (0.99 to 1.10) 1.07c (1.04 to 1.11)
4: Model 2  sVCAM-1 1.11b (1.04 to 1.19) 1.04 (0.98 to 1.10) 1.08c (1.04 to 1.11)
5: Model 2  urinary ACR 1.10b (1.03 to 1.18) 1.04 (0.99 to 1.10) 1.07c (1.04 to 1.11)
6: Model 2  vWf, sVCAM-1, ACR 1.10b (1.03 to 1.18) 1.05 (0.99 to 1.11) 1.07c (1.03 to 1.11)
7: Model 6  urinary ACR 1.10b (1.03 to 1.18) 1.04 (0.98 to 1.10) 1.07c (1.04 to 1.11)
8: Model 6  sICAM-1 1.10b (1.03 to 1.18) 1.04 (0.98 to 1.10) 1.07c (1.03 to 1.10)
9: Model 2  C-reactive protein 1.12b (1.05 to 1.20) 1.04 (0.98 to 1.10) 1.08c (1.04 to 1.11)
10: Model 2  sICAM-1 1.11b (1.04 to 1.19) 1.03 (0.98 to 1.09) 1.07c (1.04 to 1.11)
11: Model 2  C-reactive protein, sICAM-1 1.11b (1.04 to 1.19) 1.04 (0.98 to 1.10) 1.07c (1.04 to 1.11)
avWF, urinary ACR, and C-reactive protein were transformed to natural logarithm (ln).
bP  0.01.
cP  0.001.
Figure 2. Proportion of participants without cardiovascular death according to tertiles of estimated GFR (eGFR), adjusted for age,
gender, and glucose tolerance status (Cox regression analysis).
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changes in endothelial cell properties and increased inflamma-
tion play an important role in the initiation and the progression
of the atherothrombotic process (6) and on observations that
patients with renal dysfunction show evidence of endothelial
dysfunction and inflammation (13,14).
This study demonstrates that endothelial dysfunction is re-
lated to renal function in an elderly general population in
whom renal function was only mildly impaired but cannot
establish whether endothelial dysfunction causes impairment
of GFR or vice versa or that a third variable causes both. Endo-
thelial dysfunction may be an important mechanism linking
mildly impaired renal function to cardiovascular disease, be-
cause healthy endothelium normally has antiatherothrombotic
properties, such as promotion of vasodilation and inhibition of
vascular smooth muscle cell proliferation, thrombosis, and in-
flammatory activity. Many of these functions are mediated by
the release of compounds with specific biologic properties, such
as nitric oxide, proteins involved in hemostasis and fibrinolysis,
adhesion molecules, and selectins. The plasma concentrations
of such substances are thought to reflect endothelial function
status. vWf, which has prothrombogenic properties through its
involvement in platelet adhesion and aggregation and in blood
coagulation (23), has been suggested to be a marker of gener-
alized endothelial dysfunction (24). VCAM-1 is involved in the
recruitment of mononuclear blood cells into the vascular wall
(25). Soluble VCAM-1 in plasma is derived from shedding of
endothelial cells and has also been related to endothelial
dysfunction (26). In the absence of significant excretion of
sVCAM-1 in the urine (27), plasma sVCAM-1 concentration can
be regarded as a reflection of endothelial release. Finally, mi-
croalbuminuria is often regarded as a marker of generalized
endothelial dysfunction and has been shown to be indepen-
dently associated with impaired endothelium-dependent vaso-
dilation (28). In accordance with the concept that these markers
reflect endothelial dysfunction, vWf, sVCAM-1, and (mi-
cro)albuminuria all have been associated with increased risk for
cardiovascular and all-cause mortality (7–9).
This is the first population-based study to show that mildly
impaired renal function is associated with endothelial dysfunc-
tion. Instead, some studies have suggested that microalbumin-
uria is associated with glomerular hyperfiltration (29,30). For
example, in the PREVEND study, individuals with microalbu-
minuria, as compared with those with normoalbuminuria, had
a higher mean creatinine clearance (97 versus 90 ml/min per
1.73 m2) (29). In contrast, we observed a linear inverse relation-
ship between eGFR and ln ACR. This discrepancy may be
related to the higher mean age and the lower mean eGFR in the
current compared with these previous studies (29,30).
In our study, no significant relation was found between renal
function and inflammation, as estimated with sICAM-1 and
CRP. In patients with more advanced predialysis renal insuffi-
ciency, plasma sICAM-1 (14,31) and CRP (14,32) have been
shown to be elevated. The relationship between mildly im-
paired renal function and CRP is less clear. In another commu-
nity-based, nondiabetic population, Stuveling et al. (33) found
that CRP was related with both diminished and high creatinine
clearance (i.e., a U-shaped relationship). As in our study, the
positive relationship between CRP and eCC disappeared after
adjustment for BMI. This is probably due to the strong positive
relationship between CRP and BMI (34,35), which may be ex-
plained by the finding that IL-6, a regulator of the synthesis of
CRP in the liver, has been shown to be secreted by human
subcutaneous adipose tissue (36). As neither serum creatinine
nor eGFR was significantly related with CRP, it is unlikely that
a true association between CRP and eCC was masked by over-
adjustment for BMI.
Mild renal function impairment was associated with cardio-
vascular and all-cause mortality during up to 13 yr of follow-
up, in a way that was independent of conventional risk factors
for cardiovascular disease. Recent studies, with a shorter fol-
low-up, have also demonstrated that mildly decreased GFR is
an independent risk factor for cardiovascular disease (3,4).
Compared with our previous study of the same cohort (5), this
study consisted of older individuals, had a longer follow-up
and more mortality cases, and, therefore, more power to iden-
tify and quantify influences of individual risk factors on car-
diovascular and all-cause mortality. A major and new finding
of our study is that the association of renal function and car-
diovascular mortality was attenuated after adjustment for en-
dothelial function, suggesting that the relationship may be
partially explained by endothelial dysfunction.
It is likely that the change in RR for cardiovascular mortality
associated with a decrease in eGFR of 5 ml/min per 1.73 m2
from 1.22 to 1.12, which was caused by adjustment for biochem-
ical markers of endothelial dysfunction, is an underestimation
of the true impact of endothelial dysfunction in individuals
with mildly impaired renal function. The markers of endothe-
lial dysfunction that we used reflect only selected aspects of a
complex biologic entity; for example, these markers contain no
(or at most very indirect) information on endothelial nitric
oxide synthesis, which is known to be impaired in individuals
with impaired renal function (37) and which is likely to play an
important role in the association between impaired renal func-
tion and atherothrombosis (38). In this respect, it is noteworthy
that the three endothelial function markers that we used (vWf,
sVCAM-1, and ACR) contributed mutually independently to the
association between impaired renal function and cardiovascu-
lar mortality, suggesting that these various aspects of endothe-
lial dysfunction all are relevant. Furthermore, misclassification
of the 31 patients who had an unknown cause of death may
have caused underestimation of the impact of endothelial dys-
function on cardiovascular mortality.
We used ACR as a marker of endothelial dysfunction. How-
ever, it has been suggested that microalbuminuria may some-
times reflect increased albumin excretion by the kidney without
generalized endothelial dysfunction (21,39). An alternative ex-
planation of our data, therefore, is that decreased eGFR and
increased ACR are related to cardiovascular mortality through
similar mechanisms that (in part) have nothing to do with
endothelial dysfunction. We cannot exclude this, but the RR of
cardiovascular mortality decreased also when we adjusted for
endothelial function assessed by vWf and sVCAM-1 without
ACR, although to a lesser extent.
In this study, there was no relation between markers of
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inflammation and renal function or renal function–associated
mortality. However, such relations may have been underesti-
mated, because only CRP and sICAM-1 were used as parame-
ters of inflammation. Although both are predictors of cardio-
vascular disease (8,10,11), they may only partially reflect the
state of chronic inflammation. Whether other important mark-
ers of inflammation (e.g., TNF-, IL-6, secretory phospholipase
A2) explain renal insufficiency–associated cardiovascular mor-
tality requires further investigation. A limitation of our data is
that we studied a relatively healthy, elderly white population.
Therefore, it remains to be investigated whether the results of
our study can be generalized to individuals who are younger,
nonwhite, or at high risk for cardiovascular morbidity and
mortality.
Conclusion
In this population-based study, endothelial dysfunction but
not inflammation was related to renal function and seemed to
contribute to cardiovascular mortality in mild renal insuffi-
ciency. The results of this study may be clinically relevant
because endothelial dysfunction is potentially reversible (40). In
the prevention of cardiovascular disease in mild renal insuffi-
ciency, targeting of endothelial dysfunction therefore might be
an early treatment goal.
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